Biblio

Author Title [ Type

] Year

Filters: Author is Gurnari, Carmelo [Clear All Filters]

Journal Article

Falconi G, Fabiani E, Criscuolo M, Fianchi L, Finelli C, Cerqui E, Pelosi E, Screnci M, Gurnari C, Zangrilli I, et al. Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Leuk Res. 2019;84:106191.

Gagelmann N, Hobbs GS, Campodonico E, Helbig G, Novak P, Schroeder T, Schneider A, Rautenberg C, Reinhardt HChristian, Bosques L, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol. 2024.

Pagliuca S, Gurnari C, Awada H, Kishtagari A, Kongkiatkamon S, Terkawi L, Zawit M, Guan Y, LaFramboise T, Jha BK, et al. The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders. Blood. 2021.

Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso MTeresa, Cerretti R, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023.

Trinh BQ, Ummarino S, Zhang Y, Ebralidze AK, Bassal MA, Nguyen TMinh, Heller G, Coffey R, Tenen DE, van der Kouwe E, et al. Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021.

Gurnari C, Spadea M, Muratori R, Jimenez V, Radici V, Torrado S, Desai N, Ropero J, Muhsen IN, Ibrahimova A, et al. Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians. Lancet Haematol. 2023;10(7):e492-e494.

Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol FR, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023.

Gurnari C, Xie Z, Zeidan AM. How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms. Clin Hematol Int. 2022.

Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.

Chlon TM, Stepanchick E, Hershberger CE, Daniels NJ, Hueneman KM, Davis AKuenzi, Choi K, Zheng Y, Gurnari C, Haferlach T, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021.

Travaglini S, Gurnari C, Antonelli S, Marchesi F, De Angelis G, Ottone T, Divona M, Cristiano A, Hajrullaj H, Mengarelli A, et al. Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept. Br J Haematol. 2023.

Gurnari C, Visconte V. From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers. Leuk Res. 2023;127:107038.

Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldes A, Stölzel F, Rathje K, Fischer L, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024:JCO2302232.

Awada H, Gurnari C, Visconte V, Durmaz A, Kuzmanovic T, Awada H, Tu ZJin, Cook JR, Bolwell BJ, Sobecks R, et al. Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders. Leukemia. 2024.

Bruno A, Gurnari C, Alexander T, Snowden JA, Greco R. Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation. J Allergy Clin Immunol. 2023.